0006| Volume 128, SUPPLEMENT , 154969, March 2022

Blood based biomarkers as non-invasive screening tools for hepatic fibrosis in subjects with Type 2 Diabetes Mellitus

      Background: NAFLD is dramatically increasing in parallel with the pandemic of Type 2 Diabetes Mellitus (T2DM). Objectives: We aimed to assess the performance of the most commonly used non-invasive blood biomarkers for liver fibrosis in subjects with T2DM.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect